Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: A randomized, placebo-controlled trial

Vaccine

Volumn 27, Issue 49, 2009, Pages 6887-6893

  Kanungo, Suman ^a   Paisley, Allison ^b   Lopez, Anna Lena ^b   Bhattacharya, Mihir ^a   Manna, Byomkesh ^a   Kim, Deok Ryun ^b   Han, Seung Hyun ^b,e   Attridge, Stephen ^d   Carbis, Rodney ^b   Rao, Raman ^c   Holmgren, Jan ^d   Clemens, John D ^b   Sur, Dipika ^a  

^a NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^b International Vaccine Institute   (South Korea)

^c Shantha Biotechnics Limited   (India)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e Seoul National University   (South Korea)

Author keywords

Cholera; Immunogenicity; India; Safety; Vaccine

Indexed keywords

CHOLERA VACCINE; DIVALENT CATION; INACTIVATED VACCINE; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANOREXIA; ANTIBODY TITER; ARTICLE; CHILD; CHOLERA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; ENDEMIC DISEASE; FEMALE; FEVER; GROUPS BY AGE; HUMAN; IMMUNE RESPONSE; INDIA; INFANT; MALE; NAUSEA; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE DRUG DOSE; VIBRIO CHOLERAE; VOMITING; WHOLE CELL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; CHOLERA; CHOLERA VACCINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INDIA; INFANT; MALE; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 70350564865     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.008     Document Type: Article

References (21)

1. WHO. Cholera in Zimbabwe. Update 4. 2009 [cited 2009 July 28, 2009]; Available from: http://www.who.int/csr/don/2009_06_09/en/index.html.
2. OCHA. Cholera situation in Zimbabwe: daily cholera update 24 July 2009. [cited 13 August 2009]; Available from: http://ochaonline.un.org/CholeraSituation/CholeraSituation/tabid/5399/language/en-US/Default.aspx.
3. Cholera vaccines. Wkly Epidemiol Rec 76 16 (2001) 117-124
4. Naficy A., Rao M.R., Paquet C., Antona D., Sorkin A., and Clemens J.D. Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings: a cost-effectiveness analysis. JAMA 279 7 (1998) 521-525
5. Sack D.A. Cholera vaccine in refugee settings. JAMA 280 7 (1998) 600-602
6. Use of the two-dose oral cholera vaccine in the context of a major natural disaster report of a mass vaccination campaign in Aceh Province, Indonesia (2005), World Health Organization
7. Anh D.D., Canh do G., Lopez A.L., Thiem V.D., Long P., Son N.H., et al. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 25 6 (2007) 1149-1155
8. Mahalanabis D., Lopez A.L., Sur D., Deen J., Manna B., Kanungo S., et al. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS ONE 3 6 (2008) e2323
9. Albert M.J., Qadri F., Wahed M.A., Ahmed T., Rahman A.S., Ahmed F., et al. Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine. J Infect Dis 187 6 (2003) 909-913
10. Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for industry-clinical safety data management: definitions and standards for expedited reporting (1995). http://www.fda.gov/cder/guidance/iche2a.pdf [cited 2009 January 6]; Available from: http://www.fda.gov/cder/guidance/iche2a.pdf
11. Jertborn M., Svennerholm A.M., and Holmgren J. Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J Clin Microbiol 24 2 (1986) 203-209
12. Attridge S.R., Johansson C., Trach D.D., Qadri F., and Svennerholm A.M. Sensitive microplate assay for detection of bactericidal antibodies to Vibrio cholerae O139. Clin Diagn Lab Immunol 9 2 (2002) 383-387
13. Qadri F., Svennerholm A.M., Shamsuzzaman S., Bhuiyan T.R., Harris J.B., Ghosh A.N., et al. Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh. Infect Immun 73 10 (2005) 6577-6583
14. Losonsky G.A., Yunyongying J., Lim V., Reymann M., Lim Y.L., Wasserman S.S., et al. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect Immun 64 1 (1996) 10-15
15. Rao M.R., Blackwelder W.C., Troendle J.F., Naficy A.B., and Clemens J.D. Sample size determination for phase II studies of new vaccines. Vaccine 20 27-28 (2002) 3364-3369
16. Clemens J.D., Stanton B.F., Chakraborty J., Sack D.A., Khan M.R., Huda S., et al. B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. J Infect Dis 155 1 (1987) 79-85
17. Karlsen T.H., Sommerfelt H., Klomstad S., Andersen P.K., Strand T.A., Ulvik R.J., et al. Intestinal and systemic immune responses to an oral cholera toxoid B subunit whole-cell vaccine administered during zinc supplementation. Infect Immun 71 7 (2003) 3909-3913
18. Gotuzzo E., Butron B., Seas C., Penny M., Ruiz R., Losonsky G., et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun 61 9 (1993) 3994-3997
19. Taylor D.N., Cardenas V., Perez J., Puga R., and Svennerholm A.M. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children. Am J Trop Med Hyg 61 6 (1999) 869-873
20. Guidelines for the production and control of inactivated oral cholera vaccines. WHO Expert Committee on Biological Standardization. Fifty-second report. Geneva, Switzerland: WHO; 2001.
21. Losonsky G.A., Lim Y., Motamedi P., Comstock L.E., Johnson J.A., Morris Jr. J.G., et al. Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity. Clin Diagn Lab Immunol 4 3 (1997) 264-269